The diagnosis and management of erythrocytosis

BMJ (Online)

Volumn 347, Issue , 2013, Pages

  Keohane, Clodagh ^a   McMullin, Mary Frances ^b   Harrison, Claire ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BUSULFAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYUREA; JANUS KINASE INHIBITOR; PLACEBO; THEOPHYLLINE;

BLEEDING; BLOOD VISCOSITY; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE ASSOCIATION; ERYTHROCYTOSIS; HOSPITAL CARE; HUMAN; HYPOXIA; LEUKEMIA; LOW DRUG DOSE; PATIENT CARE; PHLEBOTOMY; POLYCYTHEMIA VERA; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY;

HUMANS; POLYCYTHEMIA;

EID: 84888231499     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f6667     Document Type: Review

References (35)

1. Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma 2013; published online 29 Jul.
2. McMullin MF, Bareford D, Campbell P, Green AR, Harrison C, Hunt B, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 2005;130:174-95.
3. Burge PS, Johnson WS, Prankerd TA. Morbidity and mortality in pseudopolycythaemia. Lancet 1975;1:1266-9.
4. Weinreb NJ, Shih CF. Spurious polycythemia. Semin Hematol 1975;12:397-407.
5. Lowe GD. Rheological influences on thrombosis. Baillieres Best Pract Res Clin Haematol 1999;12:435-49.
6. Messinezy M, Pearson TC. A retrospective study of apparent and relative polycythaemia: associated factors and early outcome. Clin Lab Haematol 1990;12:121-9.
7. Gagnon DR, Zhang TJ, Brand FN, Kannel WB. Hematocrit and the risk of cardiovascular disease - the Framingham study: a 34-year follow-up. Am Heart J 1994;127:674-82.
8. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
9. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51.
10. Messinezy M, Macdonald LM, Nunan TO, Westwood NB, Chinn S, Pearson TC. Spleen sizing by ultrasound in polycythaemia and thrombocythaemia: comparison with SPECT. Br J Haematol 1997;98:103-7.
11. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117:755-61.
12. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995;123:656-64.
13. Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood 2009;114:759-63.
14. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986;23:132-43.
15. Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013;368:22-33.
16. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-24.
17. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005;23:2224-32.
18. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000;110:577-83.
19. Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 2011;29:3907-13.
20. Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol 2003;74:26-31.
21. Criner GJ. Effects of long-term oxygen therapy on mortality and morbidity. Respir Care 2000;45:105-18.
22. Cranston JM, Crockett AJ, Moss JR, Alpers JH. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;4:CD001744.
23. Crockett AJ, Cranston JM, Moss JR, Alpers JH. Survival on long-term oxygen therapy in chronic airflow limitation: from evidence to outcomes in the routine clinical setting. Int Med J 2001;31:448-54.
24. Stuart-Harris C, Bishop JM, Clark TJH, Dornhorst AC, Cotes JE, Flenley DC, et al. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema: report of the Medical Research Council Working Party. Lancet 1981;317:681-6.
25. Kvale PA, Cugell DW, Anthonisen NR, Timms RM, Petty TL Boylen TC, et al. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980;93:391-8.
26. Wade JP, Pearson TC, Russell RW, Wetherley-Mein G. Cerebral blood flow and blood viscosity in patients with polycythaemia secondary to hypoxic lung disease. BMJ 1981;283:689-92.
27. Wedzicha JA, Rudd RM, Apps MC, Cotter FE, Newland AC, Empey DW. Erythrapheresis in patients with polycythaemia secondary to hypoxic lung disease. BMJ 1983;286:511-4.
28. Weisse AB, Moschos CB, Frank MJ, Levinson GE, Cannilla JE, Regan TJ. Hemodynamic effects of staged hematocrit reduction in patients with stable cor pulmonale and severely elevated hematocrit levels. Am J Med 1975;58:92-8.
29. Harrison BD, Stokes TC. Secondary polycythaemia: its causes, effects and treatment. Br J Dis Chest 1982;76:313-40.
30. Perloff JK, Rosove MH, Child JS, Wright GB. Adults with cyanotic congenital heart disease: hematologic management. Ann Intern Med 1988;109:406-13.
31. Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation 2007;115:1039-50.
32. Wickre CG, Norman DJ, Bennison A, Barry JM, Bennett WM. Postrenal transplant erythrocytosis: a review of 53 patients. Kidney Int 1983;23:731-7.
33. Yildiz A, Cine N, Akkaya V, Sahin S, Ismailoglu V, Turk S, et al. Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study. Transplantation 2001;72:542-4.
34. Julian BA, Brantley RR, Barker CV, Stopka T, Gaston RS, Curtis JJ, et al. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol 1998;9:1104-8.
35. Bakris GL, Sauter ER, Hussey JL, Fisher JW, Gaber AO, Winsett R. Effects of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation. N Engl J Med 1990;323:86-90.